Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook

Roberto Latini, Serge Masson, Lidia Staszewsky

Research output: Contribution to journalArticle

Abstract

Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalExpert Review of Cardiovascular Therapy
DOIs
Publication statusAccepted/In press - Mar 16 2016

Fingerprint

Heart Failure
Pharmacology
Valsartan
Therapeutics
Neprilysin
Angiotensin Receptor Antagonists
Expert Testimony
Observational Studies
Comorbidity
Clinical Trials

Keywords

  • clinical trials
  • Heart failure
  • LCZ696
  • Pharmacological therapy
  • serelaxin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Heart failure trials on pharmacological therapy in 2015 : lessons learned and future outlook. / Latini, Roberto; Masson, Serge; Staszewsky, Lidia.

In: Expert Review of Cardiovascular Therapy, 16.03.2016, p. 1-9.

Research output: Contribution to journalArticle

@article{70d1c3d4a4b44cf6aa51bc03c3b07703,
title = "Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook",
abstract = "Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.",
keywords = "clinical trials, Heart failure, LCZ696, Pharmacological therapy, serelaxin",
author = "Roberto Latini and Serge Masson and Lidia Staszewsky",
year = "2016",
month = "3",
day = "16",
doi = "10.1586/14779072.2016.1159957",
language = "English",
pages = "1--9",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Heart failure trials on pharmacological therapy in 2015

T2 - lessons learned and future outlook

AU - Latini, Roberto

AU - Masson, Serge

AU - Staszewsky, Lidia

PY - 2016/3/16

Y1 - 2016/3/16

N2 - Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.

AB - Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.

KW - clinical trials

KW - Heart failure

KW - LCZ696

KW - Pharmacological therapy

KW - serelaxin

UR - http://www.scopus.com/inward/record.url?scp=84962539379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962539379&partnerID=8YFLogxK

U2 - 10.1586/14779072.2016.1159957

DO - 10.1586/14779072.2016.1159957

M3 - Article

AN - SCOPUS:84962539379

SP - 1

EP - 9

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

ER -